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ABSTRACT: Chlamydia trachomatis is an obligate intracellular bacterial pathogen that infects the genital and 
ocular mucosa of humans, causing infections that can lead to pelvic inflammatory disease, infertility, and blinding 
trachoma. C. pneumoniae is a respiratory pathogen that is the cause of 12–15% of community-acquired pneumo-
nia. Both chlamydial species were believed to be restricted to the epithelia of the genital, ocular, and respiratory 
mucosa; however, increasing evidence suggests that both these pathogens can be isolated from peripheral blood of 
both healthy individuals and patients with inflammatory conditions such as coronary artery disease and asthma. 
Chlamydia can also be isolated from brain tissues of patients with degenerative neurological disorders such as 
Alzheimer’s disease and multiple sclerosis, and also from certain lymphomas. An increasing number of in vitro 
studies suggest that some chlamydial species can infect immune cells, at least at low levels. These infections may 
alter immune cell function in a way that promotes chlamydial persistence in the host and contributes to the 
progression of several chronic inflammatory diseases. In this paper, we review the evidence for the growth of 
Chlamydia in immune cells, particularly monocytes/macrophages and dendritic cells, and describe how infection 
may affect the function of these cells.
KEY WORDS: Chlamydia trachcomatis, Chlamydia pneumoniae, Chlamydia psittaci, monocyte, macrophage,  
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I. CHLAMYDIAE AND THEIR UNIQUE 
PLACE IN MICROBIAL EVOLUTION
The Chlamydiae are a unique group of obligate 
intracellular pathogens that are characterized 
by their biphasic developmental cycle. They are 
parasites of a wide range of vertebrates, including 
humans, some arthropod species, and several free-
living amoebae. Four families are recognized within 
the order Chlamydiales,1 with a total of six genera 
and 13 species (Table I), namely, family Chlamy-
diaceae (Chlamydia and Chlamydophila), family 
Parachlamydiaceae (Parachlamydia acanthamoebae, 
Neochlamydia hartmannellae, Protochlamydia amoe-
bophilia), family Simkaniaceae (Simkania negevensis, 
Fritschea bemisiae), and family Waddliaceae (Waddlia 
chrondrophila). More recently, several additional 
new Chlamydiae have been reported. These include 
Pisichlamydia salmonis, Rhabdochlamydia.
The family Chlamydiaceae comprises the best-
known human and animal chlamydial pathogens. 
For a long time, the single genus, Chlamydia, 
was the only genus within this family. In 1999, 
Everrett et al.2 proposed splitting of this family 
into two families, Chlamydia and Chlamydophila, 
based on a range of phenotypic, bioecological, 
and genotypic data. Although this subdivision has 
some merits, it was done before the chlamydial 
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genome-sequencing projects had been commenced 
and hence were not informed by the wealth of 
information in the full genomes. For this reason 
as well as disagreements between human and 
animal chlamydiologists, this subdivision into the 
two genera has not been widely accepted by the 
chlamydial community.3 Current knowledge of 
chlamydial genetics, combined with a consensus 
within the chlamydial community, is in favor of 
returning to a single genus model, Chlamydia. For 
the purposes of this review, we will refer to the 
single genus, Chlamydia, within the family Chla-
mydiaceae. When Everett et al.2 proposed the split 
into two genera, they also proposed reorganizing 
the species into nine groups. This nine-species 
arrangement does make good sense and has been 
widely accepted by the majority of chlamydiolo-
gists. Within the Chlamydia/Chlamydophila genus, 
therefore, there are now nine recognized species, 
TABLE I. Taxonomy of Chlamydiae
Systematics Natural host Pathogenicity
Order Chlamydiales
Family I: Chlamydiaceae
Genus I: Chlamydia
C. trachomatis Humans Ocular, urogenital infections
C. pneumoniae Humans, horses, koalas Respiratory, ocular, urogenital infections
C. muridarum Rodents Respiratory, ocular, urogenital infections
C. suis Swine Enteritis
C. psittaci Birds Avian chlamydiosis
C. abortus Ruminants Abortion
C. pecorum Cattle, sheep, koalas Enteritis, abortion, polyarthritis, ocular, 
urogenital infections
C. felis Cats Ocular, respiratory infections
C. caviae Guinea pigs Ocular, urogenital infections
Family II: Parachlamydiaceae
Genus I: Parachlamydia
P. acanthamoebae Acanthamoeba Endosymbiont
Genus II: Neochlamydia
N. hartmannellae Hartmannella Parasite
Family III: Simkaniaceae
Genus I: Simkania
S. negevensis Humans (?) Respiratory infections
Genus II: Fritschea
F. bemisiae Insects
F. eriococci Insects
Genus III: Rhabdochlamydia
Rhabdochlamydia spp. Woodlice
Family IV: Waddliaceae
Genus I: Waddlia
W. chrondrophila Cattle, fruit bats (?) Abortion
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namely, C. trachomatis, C. muridarum, C. suis, C. 
psittaci, C. pneumoniae, C. caviae, C. felis, C. abortus, 
and C. pecorum. C. trachomatis is a common cause 
of urogenital infections in humans and is the 
agent of trachoma, one of the leading infectious 
causes of blindness worldwide. C. pneumoniae 
is another important human pathogen, mainly 
causing respiratory infections, and it is suggested 
that virtually everyone will become infected with 
C. pneumoniae at some stage of their life. There 
is also strong evidence to implicate C. pneumo-
niae in atherosclerotic cardiovascular diseases4 as 
well as some neurodegenerative diseases, such as 
Alzheimer’s disease and multiple sclerosis.5 In-
terestingly, C. pneumoniae has also been reported 
from a wide range of animals including horses, 
koalas and other Australian marsupials, frogs, and 
other reptiles.6,7 The other Chlamydia species are 
mainly veterinary pathogens affecting a wide range 
of hosts including birds, cats, sheep, cattle, pigs, 
koalas, mice, and guinea pigs. 
The second family, Parachlamydiaceae, contains 
two genera, Parachlamydia and Neochlamydia, 
which comprise amoebal endosymbionts re-
covered from both environmental and clinical 
samples. While N. hartmannellae infects and lyses 
hartmanellae, and thus may be considered as a 
parasite, the other parachlamydiae seem to have 
a mutualistic relationship with the acanthamoe-
bal host. Interestingly, P. acanthamoebae has been 
reported to infect humans and cause respiratory 
disease.8,9
The third family, Simkaniaceae, comprises two 
genera (possibly a third), Simkania negevensis and 
Fritschea bemisiae (and F.eriococci). S.negevensis was 
originally identified as a cell culture contaminant10 
but has also since been indirectly associated with 
respiratory infections.11 This organism has several 
features that differentiate it from the Chlamydiace-
ae. It is resistant to penicillins and shows a longer 
developmental cycle in vitro, up to two weeks, 
with a peculiar stationary phase.12 S.negevensis 
has also been reported to experimentally infect 
and multiply within Acanthamoeba.13
The fourth family in the Order is Waddlia, 
which comprises the unique species and genus, 
W.chondrophila, which has been associated with 
the induction of abortion in cattle14 and can also 
enter and replicate within human macrophages.15 
W. chondrophila infection resulted in lysis and death 
of human macrophages. 
A. The Chlamydial Developmental Cycle
The chlamydial developmental cycle consists of 
two distinct morphological forms, namely, (i) the 
elementary body (EB), which is the metabolically 
inactive, extracellular, infectious stage, which is 
designed for passage between suitable host cells, 
and (ii) the reticulate body (RB), which is the 
metabolically active, replicating, intracellular 
form. The complete developmental cycle takes 
between 36 and 72 h, depending on the chla-
mydial species. Chlamydial infection is initiated 
by attachment of an EB to the host, via as yet 
uncharacterized receptors. There is evidence, 
however, for the involvement of heparin sulphate 
because it, or heparinase treatment, is able to in-
hibit the infectivity of C. trachomatis serovars L2.16 
These molecules are glycosamino glycans (GAGs) 
that are thought to have an effect on infectivity 
via nonspecific charge-mediated interactions or 
via interaction with the major outer membrane 
protein (MOMP).17 The process of chlamydial 
entry into susceptible cells is not fully understood 
but two mechanisms have been suggested, namely, 
(i) phagocytosis (microfilament dependent)18 or 
(ii) receptor-mediated endocytosis.19 Chlamydiae 
have been reported to enter the host cell via both 
mechanisms, depending on the chlamydial strain, 
the host cell, and other conditions.20 Once entry 
occurs, the chlamydial EB becomes internalized in 
a double-membraned inclusion and, importantly, 
it is dissociated from the endocytic pathway of the 
host cell, but does enter early into the anterograde 
pathway of the Golgi apparatus, avoiding phago-
lysosomal fusion. In epithelial cells, the inclusion 
does not acquire lysosomal markers but does fuse 
with trans-Golgi network-derived sphingolipid-
containing secretory vesicles.21 The inclusion also 
becomes surrounded with transferrin-containing 
endosomes very early after infection, although no 
fusion with these endosomes has been detected. 
These are clearly key steps in the chlamydial in-
fectious process and undoubtedly define, to some 
degree at least, which cell types are permissible 
to chlamydial infection. The double-membraned 
endosome that develops is termed the chlamydial 
inclusion and is where chlamydial replication 
occurs. The chlamydial RBs multiply by binary 
fission through 8 to 10 rounds of replication, 
filling up a large part of the expanding inclusion. 
At this stage, there is a trigger, possibly lack of 
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contact with the outer membrane as proposed 
by Hoare et al.,22 that results in RBs converting 
back to EBs ready for exit from the host cell. 
Exit has long been assumed to occur only via a 
physical lysis process, but recent work by Hybiske 
et al.23 has shown that two mechanisms of exit 
occur. Using a GFP-based approach to visual-
ize inclusions within cells by live fluorescence 
videomicroscopy, they identified two mutually 
exclusive pathways. The first mechanism, lysis, 
consisted of an ordered sequence of membrane 
permeabilisations, i.e., inclusion nucleus and 
plasma membrane rupture. The second release 
pathway was a packaged release mechanism, 
termed extrusion. This slow process resulted in 
a pinching of the inclusion, protrusion out of 
the cell within a membrane compartment, and 
ultimately detachment from the cell.
Although the developmental cycle is char-
acteristic of the family Chlamydiaceae, and is, in 
general, highly conserved between chlamydial 
species, there are differences that are worth noting. 
There appears to be differences in the attachment, 
entry, and survival of different species in mouse 
macrophages.24 It was shown that C. trachomatis 
will infect mannose receptor–positive mouse mac-
rophages better than mannose receptor–negative 
cells whereas, in contrast, C. pneumoniae will in-
fect mannose receptor–negative cells better than 
positive ones. C. psittaci infected both cells types 
equally.24 Some chlamydial species have highly 
fusogenic inclusions, such as C. trachomatis, which 
results in a single, large inclusion that fills most of 
the host cell. Other chlamydial species, such as C. 
caviae, the guinea pig strain, produce multilobed, 
independent inclusions, even when the infection 
is initiated by a single organism.25
B. Chlamydial Persistence
While the progression of EB to RB then back to 
EB is considered the mainstay of the chlamydial 
developmental cycle, it has become widely ac-
cepted in the last 10 years that a persistent phase 
also occurs. Chlamydial persistence is defined as 
a viable but noncultivable growth stage resulting 
in a long-term relationship with the infected host 
cell. Chlamydial persistence is best characterized 
in vitro but there is also significant evidence for 
its existence in vivo.26 In vitro, chlamydial persis-
tence is induced by a range of factors that stress 
the organism in some way, such as (i) amino acid 
deprivation in general, but tryptophan starvation 
in particular, (ii) iron depletion, (iii) nonlethal 
antibiotics, (iv) cytokines such as gamma inter-
feron (IFNγ), (v) phage infection, (vi) heat shock, 
and (vii) growth in monocytes. In all cases, the 
developmental cycle becomes stalled and infec-
tious EBs are not produced. The fact that RBs 
do not convert back to EBs means that when 
samples from persistent cultures are subcultured, 
they do not infect the new host cells and are 
therefore “non-infectious.” Instead, the normally 
round, 0.5–1.0 um RBs, become significantly 
enlarged and aberrant in shape, when viewed by 
electron microscopy. Perhaps the best-studied 
model of in vitro persistence is that induced by 
treatment with IFNγ. This means of inducing 
persistence is highly relevant clinically and has 
been shown to occur via depletion of the host cell 
tryptophan pool. Indeed, if tryptophan is added 
back to IFNγ-induced persistent cultures, they 
will revert to the nonpersistent, infectious state. 
Gamma interferon–induced persistence can be 
observed in C. trachomatis, C. pneumoniae, and 
C. psittaci, although differences do occur between 
the serovars of C. trachomatis.
In contrast to other persistence systems, Chla-
mydiae appear to become spontaneously persistent 
following infection of monocytes. Cell culture 
infections of freshly isolated human monocytes 
were infected with C. trachomatis serovars K27 or 
C. pneumoniae.28 In both studies, no normal RBs 
(only aberrant RBs) were observed at any time 
over the monocyte infection period and chlamyd-
ial mRNA continued to be detected, despite a 
loss of subculture infectivity. These observations 
suggest that Chlamydiae were surviving in a viable 
but culture-negative state.
In vivo, persistence has been associated with 
a range of chlamydial diseases such as trachoma, 
inclusion conjunctivitis of the newborn, genital 
tract infections, pneumonia, arthritis, and car-
diovascular disease.26 Various characteristics link 
these in vivo disease states with the well-studied 
in vitro cell culture models. Among the most 
convincing lines of evidence for persistence in 
vivo are observations of aberrant morphological 
forms in vivo, detection of biochemical markers 
of persistence, such as heat shock protein 60, 
and absence of cultivability, recurrences that oc-
Begell House Inc., http://begellhouse.com Downloaded 2009-9-10 from IP 59.100.94.89 by Prof. Ken Beagley (kiwiken55)
279Volume 29  Number 4
cur when reinfection is unlikely and evidence of 
clinical antibiotic resistance. Atypical, pleomor-
phic RBs with poorly defined outer membranes 
were observed in fibroblasts and macrophages 
in synovial membrane samples from patients 
with C. trachomatis–associated reactive arthritis, 
despite antibiotic therapy.29 C. pneumoniae forms 
of similar size to aberrant RBs have also been 
observed within macrophages in aortic valve 
samples from patients with degenerative aortic 
valve stenosis.30 In addition, mini–C. trachomatis 
forms have been observed in the total ejaculate 
and expressed prostatic secretion samples from 
patients with chronic chlamydial prostatitis31 and 
in the oviducts of mice experimentally infected 
with C. muridarum.32 More recently, Pospischil 
et al.33 presented some very convincing evidence 
for persistent forms in pigs infected with C. suis. 
Ultrastructurally, characteristic aberrant bodies 
were detected in the gut of both experimentally 
infected and naturally infected pigs.
A hallmark of chlamydial persistence is the 
ability to detect DNA or chlamydial marker 
proteins in the absence of viable Chlamydiae. 
Indeed, chlamydial DNA and (heat shock protein 
60) HSP60 are often detected in tubal biopsy 
specimens from culture-negative women with 
postinfectious tubal infertility following antibiotic 
treatment.34 In addition, chlamydial RNA has 
been detected in the absence of cultivability in 
experimental trachoma of primates35 as well as 
in synovial biopsy samples from patients with 
reactive arthritis.36 Because RNA is highly labile, 
its detection strongly suggests the presence of 
viable organisms and correlates with similar data 
indicating viable but culture-negative Chlamydiae 
in vitro.
Experimental and clinical data also provide 
evidence for reactivating persistent Chlamydiae 
in vivo. Dean et al.37 showed that C. trachomatis 
infections became reactivated in long-term stud-
ies of women with genital tract infections. They 
demonstrated recurrences of the original ompA 
genotype over 2 to 4.5 years, despite adminis-
tration of accepted antibiotic regimens. Similar 
genotyping data from Dean et al.37 and Ham-
merschlag et al.38 suggested that C.pneumoniae 
can also persist for many years after the initial 
respiratory infection.
C. Chlamydial Growth: By What Measure?
All chlamydial species are obligate intracellular 
parasites that infect and replicate inside a variety 
of cells types including epithelial cells of the fe-
male and male reproductive tracts (C. trachomatis 
serovars D–K), the conjunctival epithelium (C. 
trachomatis serovars A–C), and various respira-
tory tract tissues (C. pneumoniae). Due to the 
absolute requirement of a cellular host for the 
production of new progeny, it could be argued 
that the gold standard for demonstration of 
chlamydial replication would involve isolation of 
infectious progeny and demonstration of regrowth 
of Chlamydia in new host cells following in vitro 
culture under appropriate conditions. Although 
a difficult technique, and not one that could be 
successfully performed in many laboratories, these 
methods were used as diagnostic tests for many 
years. The observation by several groups that 
chlamydial persistence, described as a “viable but 
noncultivable growth stage resulting in a long-term 
relationship with the infected host cells,” could be 
induced in vitro by several methods made culture 
as a gold standard problematic since persistent 
forms are, by definition, noncultivable. This has 
led to the development of several methodolo-
gies to demonstrate the existence of Chlamydia 
within tissues, cells, and cell supernatants. These 
include the use of PCR-based methods to iden-
tify primary transcripts from chlamydial rRNA 
operons and mRNA for chlamydial genes associ-
ated with the bacterial protein synthetic system 
and hence metabolic activity,36 demonstration by 
direct fluorescence cytology of the production 
within the host cell of chlamydial products such 
as lipopolysaccharide (LPS),39 or identification of 
these products in the lysates of infected cells using 
immunoassays such as ELISA.40 Although all of 
these methods are accepted in the literature and 
are used in many laboratories worldwide, there is 
not always complete concordance between these 
methods and the demonstration of infectious 
progeny by reculturing on appropriate target cells. 
For example, when cynomolgus monkeys were 
infected in the conjunctival sac with C. tracho-
matis serovar C, infection was detected one week 
postinfection by all of the four methods employed 
(tissue culture, direct fluorescence cytology, PCR, 
and RNA blotting); however, both the nucleic 
acid detection methods suggested that Chlamydia 
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were present for longer periods of time than ei-
ther culture or cytology-based techniques. After 
a secondary infection, Chlamydia were detected 
in conjunctival swabs and smears for a further 
five weeks using nucleic acid detection after both 
culture and fluorescent cytology returned negative 
results.35 This study is provided as just one example 
of the fact that there is not always complete 
concordance between different methods that are 
commonly used to measure “chlamydial growth.” In 
the following sections, lack of correlation between 
methods when identifying chlamydial growth in 
non-epithelial cell types will be highlighted, but 
it is probably fair to say that an accepted gold 
standard for demonstration of viable, replicating 
Chlamydia is still to be agreed on.
II. GROWTH OF CHLAMYDIA  
IN HUMAN MONOCYTES
The association of C. trachomatis infection with 
reactive arthritis/Reiter’s syndrome and C. pneu-
moniae infection with chronic inflammatory 
conditions such as atherosclerosis/coronary artery 
disease, asthma, and chronic obstructive pulmonary 
disease (COPD), and neurological diseases such 
as Alzheimer’s disease and multiple sclerosis has 
raised the question of how Chlamydia are trans-
ported from the site of initial infection (the genital 
tract epithelium or the respiratory tract) to the 
site of inflammatory disease in the joints, vascu-
lature, or central nervous system (CNS). While it 
is possible that free EBs may travel through the 
circulation from the site of initial infection, there 
is increasing evidence (reviewed later) that mono-
cytes may serve as carriers for both C. pneumoniae 
and C. trachomatis. This has led to a large number 
of studies that have investigated the potential of 
various chlamydial species to infect monocytes/
macrophages and monocyte-derived cell lines in 
vitro. Most studies have employed monocytes 
isolated from human peripheral blood by density 
gradient centrifugation followed by plastic adher-
ence or monocyte/macrophage cell lines such as 
U-937 or THP-1 and have employed a number of 
strains of C. pneumoniae, and C. trachomatis strains 
including LGV serovars, and C. psittaci.
Yong et al.41 compared the ability of various 
human biovars of C. trachomatis to grow in human 
mononuclear phagocytes (MNPs) and found that 
none of the serovars tested were able to grow, as 
defined by reculture on HeLa cells, in phagocytes 
cultured for seven days or less prior to infection, 
and concluded that these cells were effectively 
microbicidal. However, in vitro culture of MNP 
for eight or more days prior to infection permitted 
the growth of the LGV biovar whereas trachoma 
biovars (Biovars B, C, E, and F) continued to be 
killed by these cells. Phagolysosomal fusion was 
not observed in MNPs that had been cultured for 
eight days or more prior to infection with LGV. 
Thus, differences in the ability of MNPs to support 
the growth of C. trachomatis are biovar specific and 
affected by the stage of maturation of the cells. 
Cells cultured in vitro for up to seven days did 
not support the growth of any biovar, while cells 
cultured in vitro for eight days or more could be 
productively infected with the LGV strain. The 
authors suggest that this may be due to a loss 
of oxidative metabolism as the monocytes ma-
tured to macrophages. Gerard et al.42 performed 
similar studies using C. trachomatis serovar K and 
plastic-adherent human blood monocytes. Dur-
ing 10 days of in vitro culture following infection 
with C. trachomatis serovar K, no infectious EBs, 
as defined by culture, were detected. However, 
throughout the 10-day culture period primary 
transcripts for chlamydial rRNA operons were 
present as were mRNAs encoding the chlamydial 
r-proteins S5 and L5, glycl-tRNA synthetase, the 
60-kDA cysteine-rich outer membrane protein, 
and the KDO transferase. The authors also showed 
that the HSP60 gene product was detectable by 
Western blot in infected monocytes throughout 
the 10 day culture period whereas the major outer 
membrane protein was almost absent. Transmis-
sion electron microscopy of infected monocytes 
revealed single or multiple Chlamydia present in 
aberrant inclusions that appeared not to contain 
normal reticulate bodies.27 Chlamydial growth 
arrest could not be overcome by tryptophan 
supplementation or neutralization of inflamma-
tory cytokines such as IFNα, IFNβ, or TNFα. 
The results indicate that in infected monocytes, 
Chlamydia are viable and metabolically active even 
though EBs capable of infecting epithelial cells 
are not produced. Schmitz et al.43 also used C. 
trachomatis serovar K to infect blood monocytes 
and were unable to demonstrate a productive infec-
tion as determined by titration of freeze-thawed 
and sonicated monocyte preparations on HEp-2 
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indicator cells. However, chlamydial MOMP 
antigen, demonstrated by immunofluorescence, 
was present in infected monocytes for up to 
14 days as was chlamydial LPS as measured by 
enzyme immunoassay. Levels of either MOMP 
or LPS in infected monocytes never exceeded 
levels seen at the initiation of infection, even at 
the highest multiplicity of infection (MOI) used, 
and both declined over the 14 day culture period. 
Chlamydial rRNA levels were also determined 
throughout the 14 days by hybridization with a 
commercially available DNA probe and although 
present never exceeded levels seen at initiation 
of infection and only 10% of input rRNA could 
be detected at 14 days postinfection. The authors 
concluded that serovar K does not productively 
infect blood monocytes but chlamydial antigens 
such as MOMP and LPS can be detected in cells 
for extended periods of time. Schrader et al.44 also 
infected plastic-adherent blood monocytes with C. 
trachomatis serovar K to investigate the induced 
expression of host inflammatory genes. In this 
study, infection of monocytes was assumed but 
not demonstrated. Of the time points investigated, 
4 h and 1 day postinfection were designated as 
active infection while 7 days postinfection was 
designated as a persistent infection. Interest-
ingly, many of the genes induced by infection 
(MIP-1α, MIP-1β, IL-2Rγ) were also induced 
by culture of monocytes with killed (either heat 
or UV inactivated) Chlamydia making it difficult 
to attribute the induced gene expression to an 
active infection.
Infection of human plastic-adherent mono-
cyte–derived macrophages may also affect their 
ability to function as antigen-presenting cells. Co-
culture of macrophages, infected with C. trachoma-
tis serovar K, with autologous PHA-activated T 
lymphocytes resulted in the death of the activated 
T cells. Death was by induction of apoptosis and 
was dependent on the presence of infected mac-
rophages because culture of T cells with chlamydial 
EBs in the absence of macrophages, or co-culture 
of T cells with macrophages preincubated with 
UV-inactivated chlamydial EBs, did not cause 
T cell death.45 Induction of T cell apoptosis was 
partly due to the secretion of TNFα by infected 
macrophages but also involved mechanisms that 
required direct cell-to-cell contact.46 The authors 
suggested that this could explain why persistently 
infected macrophages can escape T cell surveil-
lance and why T cell responses are reduced during 
persistent chlamydial infection.
Because C. pneumoniae infection has been 
potentially linked with atherosclerosis, Alzheimer’s 
disease, multiple sclerosis, and macular degenera-
tion, there have been many studies investigating 
the growth of this chlamydial species in mono-
cytes. 28,47–51. Airenne et al.28 infected MNP with 
C. pneumoniae Kajanni 7 at a MOI of 10. Stain-
ing of cells three days postinfection (PI) with a 
genus-specific antibody suggested that the cells 
were heavily infected with 90% of the mono-
cytes containing multiple inclusions. Inclusions 
in monocytes were smaller and contained fewer 
chlamydial particles than in HL cells. However, 
mechanical disruption of monocytes three days 
postinfection followed by reculture on fresh HL 
cells revealed no growth in HL cells despite the 
high levels of apparent infection of monocytes as 
determined by immunofluorescence. In infected 
monocytes, transcripts for chlamydial 16S rRNA 
and Crp60 were present for at least three days 
postinfection and HSP60 for seven days. Infected 
monocytes retained the ability to activate CD4 T 
cells to proliferate, suggesting that at least some 
phagolysosomal fusion had occurred allowing 
chlamydial antigens to access the MHC class 
II pathway. The data suggest that C. pneumoniae 
can form inclusions, albeit aberrant, in monocytes 
and that metabolic activity is detectable for three 
to seven days even though infectious EBs are 
not produced. Geng et al.48 also infected plastic-
adherent monocytes with C. pneumoniae strain 
TW 183 and found that the infected cells were 
resistant to apoptosis induction by 8-methoxyp-
soralen and hypercin whereas cells incubated with 
heat-inactivated Chlamydia were not protected 
from apoptosis. Immunofluorescent staining of 
infected MNP with a commercially available 
monoclonal antibody against the major outer 
membrane protein (MOMP) revealed that only 
a small percentage of MNP contained Chlamydia 
although this may be explained by the low MOI 
used in the studies. Infected monocytes secreted 
both IL-12 and IL-10 and neutralization of IL-10 
abolished the resistance to apoptosis. No attempt 
was made in this study to identify active chlamydial 
metabolism or the development of infectious EBs. 
Productive infection of plastic-adherent blood 
monocytes with C. pneumoniae Kajanni 6 has, 
however, been demonstrated50 but production of 
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EBs capable of infecting HL cells required that 
the MNP be incubated in vitro for at least three 
days prior to infection. Viable Chlamydiae were not 
recovered from monocytes infected immediately 
after isolation. This is consistent with the findings 
of Yong41 who showed that human MNP cultured 
in vitro for eight days supported the growth of C. 
trachomatis LGV strains whereas Chlamydia would 
not grow in freshly isolated MNP. Poikonen et 
al.47 were also able to infect blood monocytes 
that had been matured by two weeks of in vitro 
culture with C. pneumoniae K7. They showed that 
susceptibility to infection was highly variable rang-
ing from 0 to 630 C. pneumoniae/human genome 
equivalents in blood monocytes isolated from 
different individuals. These studies suggest that 
freshly isolated blood monocytes are resistant to 
productive C. pneumoniae infection, as defined by 
reculture on HL or other cell lines. However, if 
monocytes are cultured on plastic for three days 
or more, they become susceptible to infection. 
Although infection of monocytes may not be 
productive, the limited infection that does occur 
can affect antigen processing, cytokine production, 
and susceptibility to apoptosis.
While blood-derived MNP provide a ready 
source of human macrophages for infection stud-
ies, the cells most likely to be infected following 
respiratory C. pneumoniae infection are alveolar 
macrophages (AMs), cells that have been shown 
to be different from circulating monocytes/mac-
rophages.52 Nakajo et al.53 found that AMs from 
nonsmoking adults were able to kill C. trachomatis, 
both the LGV serovar and a clinical cervical isolate, 
following infection of AM at a MOI of 1 or 10. 
By 48 hours postinfection, no viable Chlamydia, 
as determined by culture on McCoy cells, could 
be recovered from AM lysates. These studies did 
not, however, look at killing of C. pneumoniae, 
but show that AMs readily kill C. trachomatis. 
Redecke et al.54 isolated AM from healthy male 
nonsmokers by bronchoalveolar lavage and plastic 
adherence. AMs were infected with C. pneumoniae 
CWL-029 at MOI of 4 and 40. Infection was 
determined by fluorescent cytology to identify 
intracellular Chlamydia and was evident for up to 
120 h postinfection, although the presence of infec-
tious progeny by cell culture was not demonstrated. 
Infection was associated with a dose-dependent 
release of reactive oxygen species, production of 
TNFα, IL-1β, and IL-8, and upregulation of 
HLA-DR expression. Similar staining of AMs 
from patients with chlamydial pneumonia was 
demonstrated. Gaydos et al.55 showed that viable 
C. pneumoniae 2023, as determined by reculture 
on HEp-2 cells, could be recovered from infected 
AM for at least 96 h postinfection. AM were 
infected after three days adherence to plastic tis-
sue culture plates. Although viable progeny were 
recovered, the levels of Chlamydia never exceeded 
the numbers used to infect AMs at the initiation 
of infection. Thus, although chlamydial numbers 
did not increase following growth in AMs, vi-
ability of the infecting inoculum was retained for 
sufficient time to permit transport of Chlamydia 
from the lung to other tissues. 
A. Growth of Chlamydia in Human 
Monocyte/Macrophage Cell Lines
1. THP-1 and U-937 Cells
Studies with monocyte/macrophage–derived 
cell lines such as THP-1 and U-937 have also 
revealed differences in susceptibility to infection 
with C. trachomatis serovar L2.56 C. trachomatis 
grew actively in THP-1 cells but not in U-937 
cells. Both cell lines, however, contained viable 
Chlamydia, as determined by the expression of 
unprocessed 16S rRNA, indicating that both cell 
lines were persistently infected, even though viable 
EBs were only recovered from THP-1 cells. This 
persistent infection of both cell lines spontane-
ously resolved after two months in culture even 
in the absence of antibiotic treatment. Of par-
ticular interest was the finding that both THP-1 
and U-937 cells became persistently infected 
following co-culture with Chlamydia-infected 
HeLa cells, but not by direct infection in vitro, 
producing EBs that were capable of productively 
infecting HeLa target cells. These data suggest 
that infection acquired through interaction of 
monocytes with infected epithelial cells may not 
only be different to direct infection of these cells 
by centrifugation in vitro, but also may promote 
persistence and transfer of infection to anatomical 
sites distant from the infected epithelium. Another 
study using the U-937 cell line57 demonstrated 
that chlamydial DNA encoding the major outer 
membrane (MOMP) could be detected in U-937 
cells for 150 days after infection with C. tracho-
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matis L2. Chlamydial LPS was also detectable in 
the medium of infected U-937 cells for 150 days, 
whereas chlamydial LPS was only detectable for 
14 days following infection of U-937 cells with 
C. pneumoniae TW183. Gaydos et al.55 infected 
U-937 cells that had been adhered by culture with 
myristate phorbol acetate with multiple strains 
of C. pneumoniae and were able to recover viable 
Chlamydia capable of infecting HEp-2 cells out 
to 96 h postinfection for three of the four strains 
tested. Yields of recoverable Chlamydia were, how-
ever, 2–4 logs lower than when these same strains 
were passaged through HEp-2 cells. Yamaguchi et 
al.58 used a number of human cell lines, including 
THP-1, to investigate susceptibility to infection 
with C. pneumoniae TW183. All of the three cell 
lines tested [Molt 4 (T cell), P3HR1 (B cell), and 
THP-1 (monocyte)] supported the growth of C. 
pneumoniae as determined by both LPS ELISA 
and reculture of cell lysates on HEp-2 cells. At 
24 and 48 h postinfection, there was at least a 
10-fold increase in infectious progeny from all 
three cell lines while infection of HEp-2 cells 
at the same MOI (10:1) resulted in more than a 
100-fold increase. Morphologically, the inclusions 
in the cell lines were small compared to those in 
HEp-2 cells and contained small irregular RBs. 
The same group49 showed that infection of THP-1 
monocytic cells with C. pneumoniae induced 
differentiation of these cells into macrophages 
as demonstrated by changes in cell morphology, 
increased phagocytosis of polystyrene beads, and 
increased expression of ICAM-1. Treatment of 
cells with heat-killed organisms did not cause 
increased phagocytic activity or morphologi-
cal changes but did result in increased surface 
expression of ICAM-1. Similarly, infection of 
peripheral blood monocytes with C. pneumoniae 
also increased the phagocytic activity of these cells 
in two or three donors tested, although incuba-
tion with heat-killed Chlamydia also increased 
phagocytic activity of human MNPs. 
2. Mono Mac 6 Cells
Heinemann et al.59 used another human mono-
cytic cell line, Mono Mac 6, to demonstrate that 
C. pneumoniae TW-183 could productively infect 
monocytes/macrophages. At 96 h PI, there was 
a 10-fold increase in infectious C. pneumoniae 
as determined by culture on HeLa cells. At the 
MOI used (10), approximately one in six Mono 
Mac 6 cells contained inclusions at 48 h PI. The 
inclusions showed a typical morphology containing 
all developmental forms of Chlamydia including 
RBs in the process of binary fission as well as 
EBs. Infection was sustained in the cells for at 
least two weeks; however, at this time, the viability 
of the cells had dropped to 20%, suggesting that 
infection was cytotoxic. The authors concluded 
that the Mono Mac 6 cell line is more susceptible 
to infection than U-937 cells because it has a 
more mature and differentiated phenotype. This 
hypothesis is consistent with the several studies 
showing that although freshly isolated peripheral 
blood monocytes cannot be infected with Chla-
mydia, these cells are readily infected following 
a period of in vitro culture to differentiate these 
cells to macrophages.41,47,50
3. The Affect of Chlamydial Infection on 
Cytokine Secretion, Apoptosis, and 
NF-κB Activation
Infection of Mono Mac 6 cells with C. pneumoniae 
also resulted in the secretion of cytokines TNFα, 
IL-6, and IL-1β by infected cells. Production of 
TNFα was rapid, peaking at 8 h postinfection 
and reaching levels reported to actually inhibit C. 
trachomatis infection of HEp-2 cells.60 Infection 
of Mono Mac 6 cells with C. pneumoniae also 
induced rapid activation of NF-κΒ, which was 
maximal at 1 h postinfection.61 Pretreatment of 
cells with inhibitors of NF-κΒ prior to infection 
resulted in activation of caspase-3 and increased 
levels of apoptotic cell death in infected mono-
cytes/macrophages.61 These studies suggest that 
activation of NF-κΒ in C. pneumoniae–infected 
Mono Mac 6 cells may protect against apoptosis 
and, if this occurs in monocytes in vivo, could 
contribute to the systemic spread of Chlamydia 
from the site of initial infection. 
Recent studies62 showing that active C. tracho-
matis L2 infection causes the selective downregula-
tion of tumor necrosis factor receptor 1 (TNFR1) 
on the surface of infected cells, including U-937 
monocytic cells, may offer an explanation as to why 
monocyte/macrophage cells can be productively 
infected in the presence of cytokines known to 
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enhance bactericidal activity. TNFR1 in infected 
cells accumulated at the chlamydial inclusion and 
was shed by infected cells into the culture superna-
tant. Receptor shedding required activation of the 
MEK-ERK pathway and the metalloproteinase 
TACE (TNFα converting enzyme). Interest-
ingly, C. psittaci infection, or exposure to inacti-
vated Chlamydia, also modulates the expression of 
TNFα receptors on HeLa cells.63 Negating the 
microbicidal effects of TNFα production through 
downregulation of TNFR1 expression may be 
one of several strategies employed by Chlamydia 
to enable growth in monocyte/macrophage cells 
and possibly other cell types. Other strategies 
may involve the inhibition of apoptosis, thereby 
increasing the life span of the infected monocyte/
macrophage and the chance for spread of infection 
and the induction of monocyte maturation into 
macrophages, which may more readily support 
chlamydial growth. 
B. Growth of Chlamydia in Murine 
Macrophages and Cell Lines
1. Peritoneal Cavity Macrophages
Early studies using mouse thioglycolate–activated 
peritoneal cavity macrophages (PerCMs)64 showed 
that both C. trachomatis serovar B and L2 were cy-
totoxic for these cells at high MOI. Approximately 
half of cultured PerCM were killed after four to six 
hours of culture with serovar B (MOI 30) or L2 
(MOI 250). Toxicity was reduced to background 
levels when the MOI was reduced 10-fold. To 
affect cytotoxicity, phagocytosis of Chlamydia was 
required although replication was not. At lower 
MOI, growth of the L2 serovar in PerCMs was 
significantly greater than the trachoma serovar,65 
consistent with the infection of macrophages 
seen in lymphogranuloma venereum. Studies by 
Wyrick66,67 used C. psittaci to infect PerCMs and 
showed that at low MOI (≤1) Chlamydia were 
able to infect and grow in these cells while at 
higher MOI (100) the Chlamydia were toxic for 
PerCMs. The toxicity of Chlamydia for PerCMs 
at high MOI was abolished by heat treatment of 
the Chlamydia. Collectively, these studies showed 
that PerCMs could be infected by C. trachomatis 
and C. psittaci at low MOI but that both species 
were toxic at higher MOIs. 
2. Alveolar Macrophages
The targets of infection with C. pneumoniae, a 
respiratory pathogen, are alveolar macrophages, 
cells that have been shown to be different from 
tissue macrophages.52 Haranaga et al.68 therefore 
used a cell line derived from murine alveolar 
macrophages (MH-S cells) and primary mouse 
alveolar macrophages to determine if these cells 
could support the replication of C. pneumoniae 
AR-39. Both the cell line and primary alveolar 
macrophages contained chlamydial inclusions, 
as determined by fluorescence cytology, when 
stained 48 h after being infected at an MOI of 1. 
However, reculture of lysates of infected MH-S 
cells on HEp-2 cell monolayers showed that IFU 
numbers did not increase above levels present at the 
initiation of infection, despite the fact that chla-
mydial LPS levels in extracts of infected primary 
macrophages and MH-S cells, as determined by 
ELISA, increased significantly over 48 h. Expres-
sion of HSP60 mRNA, but not omcB mRNA, was 
also increased 48 h postinfection. Interestingly, 
both primary alveolar macrophages and MH-S 
cells secreted high levels of TNFα when infected 
with viable Chlamydia and neutralization of TNF 
resulted in increased numbers of cells positive for 
chlamydial inclusions. Neutralization of TNF 
also resulted in increased production of HSP60 
mRNA and LPS in infected MH-S cells. These 
data suggest that growth of Chlamydia in murine 
alveolar macrophages, at least as far as production 
of infectious progeny, is restricted and that the 
production of TNFα by infected macrophages may 
be one of the mechanisms that restrict growth. 
Unfortunately, the studies by Haranaga68 did not 
look at expression of TNF receptors on MH-S 
cells to determine if these are downregulated by 
infection, as is seen in human U-937 cells follow-
ing infection with C. trachomatis.62 
3. Bone Marrow–Derived Macrophages
Bone marrow–derived macrophages (BMMs) 
grown from bone marrow precursors by culture in 
macrophage colony stimulating factor (M-CSF) 
represent another source of mouse macrophages 
that have been used for growth studies. Infec-
tion of BMMs with C. pneumoniae69 resulted 
in expression of IFNγ mRNA and protein early 
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after infection. Production of IFNγ was transient 
and required both bacterial and host cell protein 
synthesis, was independent of IL-12 production, 
and was regulated by IL-10. Production of type 1 
interferons (IFNα/β) was also required for IFNγ 
production, and both types of interferons were 
essential for control of C. pneumoniae infection 
in BMMs, which was mediated by inducible 
NO synthase (iNOS). Interferon production by 
infected BMMs is regulated by IRAK4 signaling 
and involves activation of NF-κΒ70 as well as a 
TLR4-MyD88-IFNαβ-STAT1–dependent path-
way.71 Thus, although BMMs can be infected with 
C. pneumoniae, as demonstrated by the production 
of progeny capable of infecting HL cells,69 follow-
ing infection, BMMs rapidly activate interferon-
mediated protective mechanisms to limit further 
intracellular bacterial growth. 
C. Chlamydia Pneumoniae Infection 
Affects Macrophage Adherence and 
Migration
In addition to providing a means of transport out 
of the lungs, infection of macrophages with C. 
pneumoniae also affects the adherence and migra-
tion properties of macrophages facilitating accu-
mulation in plaques and potentially transmigration 
of the blood-brain barrier. Infection of human 
peripheral blood monocytes with C. pneumoniae 
(TW-183) enhanced monocyte adhesion to aortic 
endothelial cells in a time- and dose-dependent 
manner compared to noninfected monocytes.72 
Culture of monocytes with heat- or UV-treated 
Chlamydia also increased monocyte adherence, and 
treatment of monocytes with purified Chlamydia 
LPS alone was sufficient to increase adherence to 
aortic endothelial cells,72 suggesting that actual 
infection of macrophages may not be necessary 
for increased adherence. Kaul73 also found that 
infection of human blood monocytes with C. pneu-
moniae (VR1310) increased adherence to human 
coronary artery endothelial cells (HCAECs) and 
human coronary smooth muscle cells (HCSMCs). 
The presence of chlamydial inclusions in infected 
monocytes was demonstrated by fluorescent cytol-
ogy. In this study, however, culture of monocytes 
with heat-killed Chlamydia did not result in 
enhanced adhesion to HCAECs or HCSMCs. 
May et al.74 infected the mouse macrophage cell 
line ANA-1 with C. pneumoniae (CM1) for 48 h 
before infected and noninfected macrophages were 
fluorescently labeled and infused into the right 
jugular vein of naive C57 mice. Chlamydia-infected 
ANA-1 cells showed both enhanced rolling on, 
and adherence to, the vessel wall compared to 
noninfected macrophages. Infection of human 
monocytic Mono Mac 6 cells with C. pneumoniae 
also enhanced in vitro adherence of these cells to 
human umbilical vein endothelial cell monolayers 
(HUVECs) and transmigration through mono-
layers of endothelial-like ECV604 cells.74 When 
human blood monocytes were infected with either 
C. pneumoniae or C. trachomatis (L2) such that 30% 
of cells were positive for chlamydial inclusions, 
only cells infected with C. pneumoniae showed 
increased adhesion to HUVEC monolayers. 
Equivalent adherence of C. trachomatis–infected 
monocytes only occurred when 70% of the cells 
were infected.74 Cell adhesion was inhibited by 
antibodies against VLA-4, LFA-1, MAC-1, or 
urokinase receptor.74 In these studies, polymyxin 
B did not affect C. pneumoniae–induced adhesion, 
indicating that chlamydial LPS was not involved in 
upregulation of adhesion. This is in contradiction 
to the findings of Kalayoglu,72 which showed that 
LPS did increase blood monocyte adhesion. 
In vitro studies using PerCM from green 
fluorescent protein (GFP) transgenic mice in-
fected with C. pneumoniae AR-39 demonstrated 
that infected macrophages adhered better than 
control macrophages to endothelial cells.75 The 
number of macrophages adhering to endothelial 
cell monolayers correlated with MOI used. Ex vivo 
studies also showed that infected macrophages 
adhered better than uninfected macrophages to 
aortas from both normal and hyperlipidemic mice. 
Adherence of infected macrophages to aortas 
from ICAM-1 knockout mice, however, was not 
increased, compared to noninfected macrophages 
showing that ICAM-1 is important for adher-
ence of Chlamydia-infected macrophages to the 
endothelium.
Chlamydial infection may also increase ad-
hesiveness of macrophages by directly affecting 
lipid metabolism and hence the physiochemical 
properties of the macrophage plasma membrane.76 
Chlamydia are believed to acquire certain essential 
lipids from the host eukaryotic cell77–79 since the 
chlamydial genome does not appear to provide for 
a bacterial source of these lipids. C. pneumoniae 
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infection of THP-1–derived macrophages has 
been shown to deplete membrane cholesterol, 
phosphatidylinositol, and cardiolipin but increase 
phosphatidylcholine. This resulted in increased 
membrane fluidity, enhanced macrophage fragility, 
and increased macrophage adherence to endothe-
lial cells even in the presence of inhibitors of adhe-
sion molecules,76 suggesting that host macrophage 
membrane changes resulting from infection 
contribute to chlamydial dissemination. 
C. pneumoniae infection of THP-1 mono-
cytes also stimulates monocyte transendothelial 
migration through monolayers of human brain 
endothelial cells (HBMECs).80 C. pneumoniae 
were also able to infect HBMECs and maximal 
monocyte migration was observed when both the 
monocytes and HBMECs were infected with C. 
pneumoniae. Migration into the endothelial mono-
layer involved infection-induced upregulation of 
LFA-1, VLA-4, and MAC-1 on the monocytes, 
and VCAM-1 and ICAM-1 on the endothelial 
cells.80 These studies suggest that chlamydial ef-
fects on both the local vasculature and circulat-
ing monocytes may contribute to inflammation 
in central nervous system and breaching of the 
blood-brain barrier.
D. Induction of Macrophage Foam Cell 
Formation by Chlamydia pneumoniae
Foam cell formation is the hallmark of the early 
stages of atherosclerosis. Atheroma macrophages 
accumulate excess cholesterol that is esterified and 
stored in the cytoplasm in lipid-filled vacuoles giv-
ing rise to the foamlike appearance of these cells. 
Epidemiological studies have linked atheroscle-
rosis with C. pneumoniae infection and in recent 
years there is increasing evidence that infection 
of macrophages and monocyte/macrophage cell 
lines with C. pneumoniae in the presence of low-
density lipoprotein (LDL) promotes foam cell 
formation.81–85 Foam cell formation is induced 
in human monocyte-derived macrophages,81 the 
mouse macrophage cell line (RAW-264.7),82 
and mouse peritoneal cavity macrophages84 by 
direct infection with C. pneumoniae in the pres-
ence of LDL. Chlamydial LPS82 and UV-killed 
C. pneumoniae also induced foam cell formation, 
indicating that active chlamydial infection is not 
essential for cholesterol accumulation. Foam cell 
formation is mediated by Toll-like receptor 2 
(TLR2)83 and TLR4 signaling84 and used both 
the MyD88-dependent and MyD88-independent 
pathways that involved the activation of both NF-
κΒ and IRF3.84 C. pneumoniae infection of THP-
1–derived macrophages, in the presence of LDL, 
also increased the expression of acyl-coenzyme A: 
cholesterol acyltransferase-1 (ACAT-1) mRNA 
and protein.85 ACAT-1 is the key intracellular 
microsomal enzyme that catalyzes the formation 
of cholesterol esters in many cell types.86
E. Chlamydia and Monocytes/
Macrophages: Summary 
The most consistent finding from infection studies 
with monocytes/macrophages and cell lines derived 
from these cells is that chlamydial replication, as 
measured by isolation of EBs capable of infect-
ing epithelial targets, is limited, with the majority 
of studies recovering less viable Chlamydia from 
infected macrophages than was used to initiate the 
infection. At high MOIs, many chlamydial species 
are also cytotoxic for macrophages. Maturation 
of blood monocytes to macrophages, by in vitro 
culture on plastic, in a medium containing fetal 
calf serum (FCS) may increase susceptibility to 
infection, and C. trachomatis L2 and C. pneu-
moniae are more likely to establish infections of 
macrophages than other C. trachomatis serovars. 
Infected monocytes/macrophages contain small 
aberrant inclusions, exhibit chlamydial transcrip-
tion profiles associated with persistent infection, 
and contain chlamydial LPS and HSP60, often 
for extended time periods. Infected cells appear to 
be resistant to apoptosis, and both infection and 
exposure to killed Chlamydia result in the secretion 
of a range of cytokines. Infection may also affect 
macrophage function, including phagocytic ability, 
antigen presentation, lipid metabolism leading to 
foam cell formation, and adhesion properties for 
vascular endothelium and transmigration of the 
blood brain barrier.
III. GROWTH OF CHLAMYDIA  
IN DENDRITIC CELLS
Dendritic cells are key cells for the activation of 
naive CD4 T cells and the subsequent adaptive 
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immune responses that are key for both protec-
tive immunity against Chlamydia infection as 
well as the immunopathology that can develop 
following natural infection. A number of studies 
in recent years have shown that some human and 
mouse dendritic cells can also be infected with 
Chlamydia.39,87–90 
A. C. pneumoniae Infection of Human 
Monocyte-Derived Dendritic Cells
Using dendritic cells derived f rom human 
monocytes by culture with GM-CSF and IL-4 
(MoDC), Wittkop et al.88 were able to infect 
these cells with a clinical isolate of C. pneumoniae. 
Beginning 2 h postinfection, chlamydial particles 
were found in MoDC and up to 25 days postin-
fection fluorescent chlamydial particles identified 
by staining with FITC anti-MOMP antibodies 
were detectable. The inclusions inside MoDC 
were smaller than inclusions inside HEp-2 cells. 
On day seven, postinfection inclusions containing 
EBs and RBs were easily identified by electron 
microscopy. Lysates of MoDC infected at MOIs 
of 0.5 and 2 contained chlamydial particles ca-
pable of productively infecting HEp-2 cells. After 
infection at these low MOIs, infectious Chlamydia 
were recovered for 19–25 days postinfection of 
MoDC from three different donors. In contrast, 
if MoDC were infected at a higher MOI of 10, 
no infectious progeny were detected beyond 10 
days postinfection, suggesting that the course 
of infection is determined in part by the initial 
infectious dose. Although infectious progeny 
were recovered, numbers never exceeded the 
numbers used to initially infect MoDC, show-
ing that although productive, infection is limited 
compared to infection of HEp-2 cells. Up to 14 
days postinfection, transcripts from chlamydial 
genes encoding products involved in cell divi-
sion and energy production (dnaA, ftsK, and tal) 
were detected by RT-PCR, indicative of active 
chlamydial metabolism. Further evidence of pro-
ductive infection of MoDC was provided by the 
demonstration that infected MoDC were able 
to infect macrophages in a transwell co-culture 
system that prevented direct cell-cell contact.91 C. 
pneumoniae inside infected MoDC were labeled 
with the red fluorescent dye ceramide. After three 
to five days, co-culture red-labeled Chlamydia were 
detected in macrophages in the lower compartment 
of the transwell system. Importantly, Chlamydia 
able to productively infect HEp-2 cells were re-
covered from both MoDC and the macrophages. 
In another study92 using MoDC as targets for 
C. pneumoniae infection, recoverable Chlamydia 
capable of infecting Hep-2 cells were recovered 
from lysates of infected MoDC for between 24 
and 72 h postinfection, depending on the donor; 
however, as with the findings of Wittkop,88 the 
numbers of recoverable Chlamydia never exceeded 
the number used to initiate infection of MoDC, 
suggesting only a limited duration of productive 
infection, or survival of some of the initial inocu-
lum. Chlamydial transcripts for the 16S rRNA, 
groEL-1, and OmvB genes were detected by RT-
PCR for several days postinfection and chlamydial 
LPS was detectable by immunofluorescence for 
up to 28 days. Chlamydial infection induced the 
activation of MoDC and also the secretion of 
IFNγ. Although this cytokine is important for 
protective immunity against chlamydial infection, 
antibody-mediated neutralization of IFNγ did not 
enhance chlamydial infection of MoDC.92 
B. C. trachomatis Infection of Human 
Monocyte-Derived Dendritic Cells
Because C. trachomatis–infected dendritic cells 
have been detected in synovial tissues from patients 
with reactive arthritis, Matyszak et al.39 infected 
MoDC with C. trachomatis L2. Entry of Chlamydia 
was mediated by attachment to heparin sulfates 
and could be blocked by heparin. Inhibition of 
micropinocytosis did not prevent uptake of Chla-
mydia by MoDC. At 24 h postinfection, MoDC 
were fixed with paraformaldehyde, with and 
without saponin, then stained with anti-Chlamydia 
antibodies. Without saponin permeabilization, 
only 4% of cells stained positive whereas almost 
70% of cells stained positive following treatment 
with saponin, showing that at 24 h PI, MoDC 
contained intracellular Chlamydia. Chlamydiae 
were contained in distinct vacuoles that did not 
develop into characteristic inclusion bodies. 
In this study, the presence of viable Chlamydia 
or bacterial metabolism were not assessed. C. 
trachomatis–infected MoDC secreted IL-12 and 
TNFα, but not IL-10, and were able to support 
the proliferation and expansion of both CD4 
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and CD8 T cells, demonstrating that infection of 
MoDC results in chlamydial antigen entry into 
both the MHC class II and class I presentation 
pathways. Gervassi et al.87 were able to infect 
human MoDC with both C. trachomatis serovar 
E and L2. Infection was demonstrated by im-
munofluorescence and by reculture of EBs from 
infected DC on HeLa cells. Serovar L2 resulted 
in higher rates of infection of MoDC than serovar 
E at similar MOI. Both infection and exposure 
to heat-inactivated EB resulted in upregulation 
of CD54 and CD80 on MoDC and induced 
secretion of IL-6, IL-8, IL-12p70, and TNFα. 
Interestingly, however, only actual infection of 
MoDC, but not exposure to killed Chlamydia, 
resulted in secretion of IL-1β and IL-18, and the 
processing of each of these cytokines from their 
precursors required infection-induced activation 
of caspase-1 that was not induced by exposure 
to killed EBs.87 Thus, the phenotype of MoDC 
activated by either live or inactivated EBs was 
similar, but cytokine secretion profiles differed 
between MoDC infected with live Chlamydia and 
those exposed to heat-inactivated EBs.
C. C. muridarum Infection of Mouse 
Bone Marrow–Derived Dendritic Cells
Mouse bone marrow–derived dendritic cells (BM-
DCs), grown by culture of bone marrow precursors 
in GM-CSF, either alone or in combination with 
IL-4, and murine DC cell lines such as JAWS II 
or DC2.4 have also been used as targets to study 
the growth of Chlamydia.89,90,93 Most of these 
studies have used the mouse-adapted strain of 
Chlamydia, C. muridarum. Infection of BMDCs 
at an MOI of 1 or 3 resulted in approximately 
10% of BMDCs showing atypical inclusions that 
stained with antibody against chlamydial MOMP. 
Reculture of BMDC lysates on HeLa cells showed 
that DCs contained very low levels of cultivable 
bacteria. Numbers of recoverable bacteria from 106 
BMDCs was only 300–900 at nine days postin-
fection, although only 20% of BMDCs were still 
alive at this time. Death of infected BMDCs was 
due to induction of apoptosis.93 These data show 
that BMDCs support only low-level growth of C. 
muridarum.89 However, intranasal inoculation of 
naive mice with BMDC, infected with Chlamydia 
nine days previously, resulted in weight loss and 
lung infections in recipient mice, showing that 
Chlamydia surviving in BMDCs at nine days 
postinfection can cause mouse lung infection. 
Infected BMDCs were also able to process and 
present antigen to Chlamydia-specific CD4 T 
cells isolated from mice that had been previously 
infected with C. muridarum.89 The JAWS II cell 
line derived from C57BL/6 BMDCs is also able 
to support the growth of C. muridarum 93; however, 
levels of recoverable Chlamydia from JAWS II cells 
were 10-fold greater than that from an equivalent 
number of BMDCs, suggesting the cell line was 
more supportive of chlamydial growth. Chlamydia 
infection of both BMDCs and the JAWS II cell 
line resulted in activation of cells as shown by 
upregulation of CD40, CD86, and MHC class II 
and secretion of IL-12. JAWS II cells pulsed with 
Chlamydia were also able to support proliferation 
and IFNγ secretion by Chlamydia-immune CD4 
T cells in a manner similar to Chlamydia-infected 
BMDCs.93 
Adoptive transfer of either BMDCs or 
JAWS II cells, pulsed with either live or UV-
killed Chlamydia, to naive mice was also able to 
provide protection against respiratory challenge. 
In both cases, DCs pulsed with live Chlamydia 
provided greater protection against weight loss. 
Other groups have also used Chlamydia-primed 
DCs to elicit protective immunity in mice94–96 
and have shown that production of IL-12 by 
primed DCs is essential for protection. Further-
more, suppression of IL-10, or using DCs from 
IL-10 knockout mice, further enhances protec-
tive immunity.95 Although exposure of DCs to 
inactivated Chlamydia and infection with live 
Chlamydia both cause maturation of DCs, the 
phenotype of the activated DCs differs with each 
stimulus.97,98 BMDCs exposed to live Chlamydia 
expressed high levels of MHC class II, CD80, 
CD86, CD40, and ICAM-1 and secreted high 
levels of TNFα and IL-12, whereas BMDCs 
exposed to UV-inactivated EBs expressed low 
levels of CD40 and CD86 but increased CD80, 
MHC class II, and ICAM-1 and secreted lower 
levels of inflammatory cytokines. BMDCs pulsed 
with live EBs were better at supporting prolif-
eration of Chlamydia-specific CD4 T cells than 
BMDCs pulsed with inactivated EBs and also 
provided better protection of naive hosts follow-
ing adoptive transfer and challenge.97 Exposure 
to live versus inactivated Chlamydia also resulted 
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in marked differences in CXC chemokine expres-
sion profiles.98 
Chlamydia-infected BMDCs have also been 
used as a tool to identify potential protective 
chlamydial antigens capable of activating a strong 
CD4 Th1 response.99,100 Isolation and sequencing 
of peptides eluted from class II MHC molecules of 
Chlamydia-infected BMDCs has identified several 
novel peptide antigens that can partially protect 
mice against chlamydial infection. These studies 
suggest that a combination of antigens naturally 
presented on MHC class II as a result of infec-
tion of DCs and using adjuvants that mimic the 
immune response elicited by adoptive transfer of 
infected DCs may provide a pathway toward a 
successful chlamydial vaccine for humans.
Our own recent studies90 suggest that Chla-
mydia infection of DCs may subvert their antigen-
presenting function to promote nonprotective Th2 
immunity. Infection of BALB/c BMDCs with C. 
muridarum at an MOI of 2 resulted in approxi-
mately 60% of cells staining positive for chlamydial 
inclusions after 36 h. Viable Chlamydiae capable 
of infecting McCoy cells were recovered from 
lysates of infected BMDCs. Infected BMDCs 
expressed lower levels of CD80 and increased 
CD86 compared to noninfected BMDCs, and 
infection did not increase MHC class II levels. 
All three markers (MHC II, CD80, and CD86) 
were upregulated on LPS-activated BMDCs as 
expected. Infected BMDCs secreted increased 
levels of TNFα, IL-6, IL-10, IL-12, and IL-13 
compared to noninfected BMDCs. IL-10 secre-
tion by infected BMDCs was significantly greater 
(> threefold) than in cultures of LPS-stimulated 
BMDCs used as positive controls. Of particular 
interest, however, was the effect chlamydial infec-
tion had on the antigen-presenting function of 
BMDCs. Infected BMDCs pulsed with OVA 
peptide induced five- to sixfold greater prolifera-
tion of OVA-specific transgenic DO11.10 CD4 T 
cells than noninfected BMDCs pulsed with OVA 
peptide. Furthermore, DO11.10 T cells activated 
by Chlamydia-infected BMDCs were strongly 
Th2 biased, secreting high levels of IL-10 and 
IL-13 while IFNγ secretion was reduced more 
than 20-fold compared to D10 cells that were 
cultured with noninfected BMDCs.90 Intratracheal 
adoptive transfer of Chlamydia-infected BMDCs, 
but not noninfected BMDCs, to naive mice also 
caused increased airways hyperreactivity, an animal 
model of asthma, in recipient mice. This was due 
mainly to increased IL-13 production by infected 
BMDCs. These data suggest that Chlamydia infec-
tion of BMDCs allows the pathogen to deviate 
the induced immune response from a protective 
Th1 to a nonprotective Th2 response (in BALB/c 
mice) and that in a setting of allergic airways 
inflammation this may lead to an exacerbation 
of the asthmatic phenotype.90 Interestingly, all 
of the studies showing that adoptive transfer 
of Chlamydia-pulsed DCs induced protective 
immunity against chlamydial infection93–96 used 
mice on a C57BL/6 background while our studies 
used BALB/c mice, suggesting that host genetic 
background influences the outcome of chlamydial 
infection of dendritic cells, such that atopic indi-
viduals may respond in a way that leads to chronic 
infection and exacerbation of allergic disease. 
Allergic airways diseases (AADs) such as asthma 
typically develop in early life and chlamydial infec-
tion of the airways is increasingly linked to the 
development of asthma in children.101 Early life 
immunity is dominated by Th2 responses, which 
suggests that chlamydial infections of atopic indi-
viduals may reinforce or enhance the Th2 pheno-
type of early life to promote the development of 
asthma.101 Because DCs play pivotal roles in the 
induction of adaptive responses and may deviate 
immune responses from a Th1 to Th2 phenotype 
in certain circumstances or susceptible groups, 
they are likely to be important in the induction 
of Chlamydia-associated asthma in early life. The 
immune system of early life is plastic and may 
be educated by infectious exposure. Therefore, 
chlamydial infections that reinforce DC-mediated 
Th2 responses may have permanent effects on 
immunity and promote lifelong susceptibility to 
Th2-mediated diseases such as asthma. 
D. Summary: Chlamydial  
Infection of Dendritic Cells
Several studies of DC susceptibility to chlamyd-
ial infection have isolated Chlamydia capable of 
infecting epithelial cells from infected DCs. In 
most cases, however, the amount of Chlamydia 
recovered from DCs did not exceed the amount 
of Chlamydia used to establish the initial infection. 
Adoptive transfer of infected DC to naive mice 
did however result in a chlamydial respiratory 
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infection and infected DCs were able to infect 
macrophages in a transwell culture system. Small 
irregular inclusions can be detected in DCs and 
a transcript profile suggestive of active infection 
was noted in some studies. Use of a low MOI 
led to prolonged presence of inclusions whereas 
at higher MOIs infections were of shorter du-
ration and may have been cytotoxic for DCs. 
Infection of DCs resulted in altered expression 
of surface markers associated with antigen pre-
sentation (CD40, CD80, CD86, MHC-II) and 
increased cytokine secretion. Both the phenotype 
of infected DCs and the cytokine profile differed 
from that of DCs exposed to killed Chlamydia. 
Furthermore, infected DCs were better able to 
induce proliferation of CD4 and CD8 T cells in 
vitro and to elicit protective immunity following 
adoptive transfer to mice than DCs activated by 
culture with inactivated Chlamydia. Infection of 
DCs from BALB/c mice resulted in DCs that 
induced strong Th2 immunity and suppressed Th1 
development, implying that not only are the Chla-
mydia able to actively infect DCs, but may also be 
actively altering their antigen-presenting functions. 
Chlamydia-infected DCs also exacerbated allergic 
airways disease when adoptively transferred to 
naive mice, suggesting that chlamydial infection 
of DCs in atopic individuals might reinforce the 
Th2 phenotype, resulting in exacerbation of allergic 
disease and persistent chlamydial infection.
IV. CHLAMYDIAL INFECTION OF OTHER 
LEUKOCYTE SUBSETS
In addition to infection of monocytes/macrophages 
and dendritic cells, there have been reports of 
chlamydial infection of neutrophils, mast cells, 
and T lymphocytes.
A. Neutrophils
Register103 demonstrated that both C. trachomatis 
and C. psittaci were rapidly internalized in an 
opsonin-independent manner by human poly-
morphonuclear leukocytes (PMNs). At an MOI 
of 1, approximately 60% of C. trachomatis were 
internalized by 15 min. While most internal-
ized Chlamydia appeared to be destroyed within 
peroxidase-positive phagolysosomes,104 both C. 
psittaci and C. trachomatis capable of infecting 
McCoy cells could still be recovered from PMN 
lysates at 10 h postinfection. Because PMNs are 
short-lived cells, it was suggested that the 3–7% 
of Chlamydia that remained viable at 10 h could 
be able to infect macrophages on engulfment of 
dying PMNs or potentially epithelial cells if EBs 
were released from dying PMNs. Another study105 
showed that C. pneumoniae were also rapidly 
internalized by human PMNs in an opsonin-
independent manner. These studies showed that 
following internalization, Chlamydia were not 
killed but actually survived and multiplied within 
infected PMNs. Infection was determined by 
staining of cells with anti-Chlamydia monoclo-
nal antibodies (Mabs) and also by analysis of 
the amount of chlamydial LPS within infected 
PMNs. As measured by LPS ELISA, there was 
a fivefold increase in chlamydial load in PMNs 
four days after infection. Importantly, infection 
delayed the apoptotic cell death of PMNs. While 
noninfected PMNs became apoptotic (annexin 
V and TUNEL staining) within 10 h, infected 
PMNs survived for up to 90 h. The antiapoptotic 
effect was associated with lower levels of procas-
pase-3 processing and consequently lower caspase 
3 activity in infected PMNs.105 Chlamydial LPS 
was a major bacterial component responsible for 
the observed antiapoptotic effects in addition to 
increased production of IL-8, an antiapoptotic 
cytokine, by infected PMNs. This study suggests 
that even though C. pneumoniae respiratory infec-
tion elicits a massive influx of PMNs, Chlamydia 
can extend the life span of PMNs by modulat-
ing apoptosis, thereby providing a suitable host 
cell for infection and bacterial multiplication. 
In addition to providing a permissive host cell 
for chlamydial replication, recent ultrastructural 
studies of C. caviae infection in the guinea pig 
conjunctival infection model suggest that PMNs 
may also play an active role in detaching infected 
epithelial cells from the underlying epithelium,106 
providing another mechanism for facilitating the 
spread of infection to new tissue sites.
B. Mast Cells
Because a significant number of asthmatics with 
chlamydial infections have increased numbers of 
mast cells in their airways,107 the mast cell has 
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been investigated as another potential host cell for 
Chlamydia. Culture of peripheral blood-derived 
cultured human mast cells with C. pneumoniae108 
induced message expression and secretion of IL-8, 
TNFα, and MCP-1. Induction of these inflam-
matory cytokines was reduced when mast cells 
were cultured with UV-inactivated bacteria. Ad-
ministration of live Chlamydia to apolipoprotein 
E–deficient mice also resulted in accumulation and 
activation of mouse aortic mast cells in vivo. No 
attempt however was made to isolate recoverable 
Chlamydia from mast cells, or to demonstrate 
direct infection using immunocytology in either 
study however, so with regard to infection of mast 
cells the data are still not definitive.
C. T lymphocytes
Infection of human peripheral blood lympho-
cytes, depleted of plastic-adherent cells, with 
C. pneumoniae was demonstrated in four of 11 
donors at three days postinfection by staining of 
inclusions with a genus-specific anti-Chlamydia 
Mab.40 The frequency of lymphocytes harboring 
inclusions, the number of inclusions per cell, 
and the inclusion size were all less than those 
seen in HEp-2 cells infected at the same MOI. 
Similarly, cultures of mouse spleen cells depleted 
of plastic-adherent monocytes also contained 
cells that harbored FITC-labeled inclusions three 
days postinfection. When mouse lymphocytes 
were enriched for T cells (> 95% CD3+) prior 
to infection, many T lymphocytes also contained 
chlamydial inclusions at three days. Chlamydial 
LPS, as determined by ELISA, also increased 
in mouse lymphocyte cultures over the three 
day infection period, as did the amount of omp1 
DNA.40 Infection of the human T cell line Molt 
3 with C. pneumoniae also resulted in increased 
numbers of cells harboring chlamydial inclusions 
and increased levels of chlamydial LPS in cultures 
over a three day infection.40 Despite the demon-
stration of inclusions and increased levels of LPS 
in lymphocytes and Molt 3 cells, the authors were 
unable to isolate Chlamydia able to infect HEp-2 
cells from lysates of lymphocytes or T cell lines, 
except when these were prepared immediately 
after lymphocyte infection. This further highlights 
the lack of correlation between methods used to 
identify chlamydial “infection” and suggests that 
the chlamydial developmental cycle may not be 
completed in lymphoid cells.
D. Glial Cells, Astrocytes,  
and Neuronal Cells
The recent linking of C. pneumoniae infection with 
neurological conditions such as multiple sclero-
sis109 and Alzheimer’s disease110 has stimulated 
studies of chlamydial infection of CNS-derived 
cells such as glial cells and astrocytes. Boelen et 
al.111,112 used murine astrocyte (C8D1A), neu-
ronal (NB41A3), and microglial (MMC BV-2) 
cell lines to determine susceptibility to infection 
with C. pneumoniae (TWAR 2043). Infection was 
measured by immunofluorescence, real-time PCR 
(ompA), and culture of supernatants from cell 
lines on HEp-2 indicator cells. Immunofluores-
cent staining of chlamydial inclusions suggested 
that chlamydial replication in astrocytes and 
neuronal cells was comparable to that in HEp-2 
cells (60–70% of cells contained inclusions at 24 
h postinfection) whereas chlamydial growth in 
MMC BV2 microglial cells  was greatly reduced 
(<5% of cells contained inclusions at 24 h) and 
inclusions were virtually absent at 72 h postinfec-
tion. In MMCs, the levels of chlamydial DNA did 
not increase above levels present at the initiation 
of infection whereas chlamydial DNA increased 
100- to 1000-fold in astrocytes, neuronal cells, 
and epithelial cells. Supernatants were collected 
from all four cell types one week postinfection 
and inoculated onto HEp-2 monolayers. Similarly 
high levels of infectious Chlamydia were recovered 
from HEp-2 cells and astrocytes, significantly 
less from neuronal cells, and almost no infectious 
progeny were found in the culture supernatants 
of infected MMCs. Chlamydial infection of 
astrocytes and neuronal cells, but not MMCs, 
also increased the number of necrotic cells. These 
data suggest both astrocytes and neurons are 
susceptible to infection, produce viable progeny, 
and are prone to infection-induced necrotic 
cell death whereas MMCs, cells thought to be 
derived from macrophages, are highly resistant 
to infection. Another study with the neuro-
blastoma cell line SK-N-MC however showed 
that C. pneumoniae–infected neuronal cells were 
resistant to staurosporine-induced apoptosis and 
the authors suggested that this could exacerbate 
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chronic infections in the brain.113 Although only 
small numbers of MMCs contained inclusions, 
exposure of these cells to C. pneumoniae resulted 
in the secretion of MCP-1, IL-6, TNFα, and 
IL-1β. Exposure of neurons to supernatants of 
infected MMCs, but not mock-infected MMCs, 
resulted in significant neuronal cell death. Neu-
tralization of IL-6 and TNFα in supernatants 
of infected MMCs reduced neuronal cell death 
by approximately 50%.111 Thus MMCs, although 
resistant to chlamydial infection, respond by 
secreting proinflammatory cytokines that may 
play a role in neurodegeneration. Infection of 
another mouse microglial cell line (EOC 20) with 
C. pneumoniae (TW 183) also resulted in many 
cells containing inclusions that stained positive 
with a chlamydial LPS Mab and increasing levels 
of bacterial 16S rRNA and omcB transcripts.114 
Lysates of this microglial cell line however did 
contain chlamydial EBs that productively infected 
HEp-2 cells, and by 24 h postinfection there was 
an eight- to ninefold increase in infectious prog-
eny. Infection of microglial cells rapidly induced 
expression of TNFα mRNA, as well as mRNA 
for IL-10 and IL-12. Infection of microglial cells 
also induced the selective expression of matrix-
metalloproteinase-9 (MMP-9) mRNA but not 
transcripts for MMP-2 and tissue inhibitor of 
metalloprotease-1 (TIMP-1). Both TNFα and 
MMP-9 are believed to be involved in damage 
to the myelin sheath.115,116 Human astrocyte 
and microglioma cells lines (U-87 MG and 
CHME-5, respectively) have also been infected 
with C. pneumoniae AR-39.117 Both cell types 
displayed inclusions that were indistinguishable 
from those in HEp-2 cells, and real-time PCR 
analysis showed that the accumulation of chla-
mydial DNA over time was identical to that seen 
in infected HEp-2 cells. Patterns of chlamydial 
gene transcription in astrocytes, microglia, and 
HEp-2 cells were characteristic of an acute rather 
than persistent infection.117 Collectively, these 
studies show that astrocytes in particular can be 
infected with C. pneumoniae and, importantly, 
that although microglial cells may or may not 
be productively infected, they do create a proin-
flammatory environment that may contribute to 
neurodegenerative diseases.
V. CHLAMYDIAL INFECTION OF 
IMMUNE CELLS IN DISEASE
If chlamydial infection of immune cells plays a 
role in diseases such as atherosclerosis, asthma, 
Alzheimer’s disease, and multiple sclerosis, then 
cells infected with Chlamydia should be identifi-
able in patients with these conditions. 
A. Coronary Artery Disease
Using PCR-based methods, C. pneumoniae has 
been detected in peripheral blood mononuclear 
cells isolated from patients undergoing abdominal 
aortic aneurysm surgery,118 in PBMCs of 72% of 
patients with symptomatic carotid atherosclerotic 
disease but only 30% of patients with asymp-
tomatic disease,119 in CD14+ peripheral blood 
monocytes from patients with unstable angina or 
myocardial infarction,120 in circulating leukocytes 
of 20% of patients undergoing surgery for carotid 
stenosis, aneurysm, or peripheral vascular disease 
but also 13% of normal control subjects,121 in 
PBMCs of 59% of patients admitted for coronary 
angiography but also in 46% of age-matched con-
trols,122 in plastic-adherent PBMCs, and CD3+ 
cells from coronary artery disease patients and 
normal blood donors,123 in PBMCs from 8.8% 
of men with coronary artery disease but in only 
2.9% of controls,124 and in 8.9% of PBMCs from 
normal blood donors.125 From the above studies it 
is difficult to conclude that detection of chlamydial 
DNA in circulating blood cells can be used as a 
predictor of coronary artery disease (CAD) due 
to the detection of Chlamydia in control groups 
in many of the studies. It has been suggested that 
measurement of C. pneumoniae bacterial load in pe-
ripheral blood may be useful in assessing infection 
in CAD patients126 and another study concluded 
that C. pneumoniae DNA in PBMCs is a predictor 
of CAD in men;124 however, a recent systematic 
review of 18 relevant studies127 concluded that C. 
pneumoniae DNA detection was associated with 
CAD in unadjusted case-control studies but that 
adjustment for confounders such as smoking or 
season and standardization of laboratory methods 
would be needed to confirm this association. Chla-
mydia have also been detected in 25% of PBMCs 
from normal blood donors by immunofluorescent 
microscopy of blood smears128 with neutrophils, 
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eosinophils/basophils, and monocytes all found to 
stain positive with anti-Chlamydia EB antiserum. 
Lysis of PBMCs and culture of lysates on J774 
monolayers demonstrated that PBMCs from 25% 
of donors contained infectious Chlamydia able to 
infect this murine macrophage cell line, providing 
evidence that infected circulating blood cells are a 
potential source of transmission of infection.
B. C. pneumoniae and Asthma
C. pneumoniae was detected by immunofluo-
rescent staining in smears of bronchoalveolar 
lavage (BAL) cells isolated from pediatric asthma 
patients by bronchoscopy.129 Morphological ob-
servation suggested that inclusions were present 
in alveolar macrophages and lymphocytes as well 
as epithelial cells. BAL cells isolated from 67% 
of pediatric asthma patients were also positive by 
PCR (16S rRNA) and in 33% of patients lysates 
of BAL cells contained infectious Chlamydia that 
were able to infect human or mouse monocyte/
macrophage cell lines (THP-1 and J774A.1).129 
Studies by the same group also detected C. tra-
chomatis in bronchoalveolar lavage fluid (BALF) 
obtained from pediatric patients with respira-
tory infections.130 C. trachomatis DNA in BALF 
decreased with age whereas C. pneumoniae DNA 
generally increased with age.130 Collectively, these 
studies suggest that viable C pneumonia and C. 
trachomatis occur frequently in children with 
chronic respiratory infections and may be more 
prevalent in asthma patients. The role of persistent 
chlamydial infection in adult-onset asthma and 
in exacerbation of asthma in adult asthmatics 
is presently unclear, although C.pneumoniae can 
certainly persist for many years after the initial 
respiratory infection.37,38
C. Chlamydia (Chlamydophila) psittaci 
and Lymphomas
Psittacosis is a zoonotic disease caused by C. 
psittaci and is usually contracted through contact 
with poultry or psittacine birds such as cockatoos, 
parrots, and parakeets.131 Recent evidence has sug-
gested that C. psittaci infections may be associated 
with some non-Hodgkin’s lymphomas, particularly 
ocular adnexal lymphomas (OALs).132–136 C. psit-
taci DNA was detected by PCR in 80% of OAL 
samples and all samples were negative for C. 
trachomatis and C. pneumoniae.132 None of the 
20 non-neoplastic orbital biopsies tested were 
positive for C. psittaci. Of the patients with posi-
tive lymphomas, 43% also had C. psittaci DNA 
detectable in their PBMCs while all healthy blood 
donor controls were negative.132 In a follow-up 
study,134 74% of OAL patients were positive for 
C. psittaci by PCR, immunohistochemistry, and 
immunofluorescence. Furthermore, laser-capture 
microdissection was used to show that monocytes/
macrophages were the cells infected with C. psit-
taci and intact EBs were demonstrated in these 
cells by electron microscopy. C. psittaci DNA was 
also demonstrated in some non-OAL lympho-
mas, both nodal and extranodal, and seemed to 
be more common in large B cell lymphomas of 
the skin and Waldeyer’s ring. Viable C. psittaci, 
able to productively infect J774A.1 monocyte/ 
macrophage cell monolayers, was isolated from 
PBMCs and/or conjunctival swabs of 25% of 
ocular adnexal MALT lymphomas (OAMLs) in 
a prospective case-control study by this group.136 
All patients with positive cultures had a C. 
psittaci–positive lymphoma and C. psittaci was 
not recovered from any of the normal healthy 
blood donors used as controls.136 The study au-
thors also provided epidemiological data showing 
that OAML is more common in rural areas in 
individuals who have prolonged contact with 
animals that may carry C. psittaci and who also 
have a history of chronic conjunctivitis. Treatment 
of OAL/OAML with doxycycline, an antibiotic 
known to be effective against Chlamydia, resulted 
in complete and partial remissions in up to 64% 
of patients, even in some patients with relapsed 
disease and regional lymphadenopathies.135,137 It 
should be noted however that lymphoma regres-
sion was also observed in patients with C. psit-
taci DNA-negative tumours.137 Not all studies, 
however, have supported a link between C. psittaci 
infection and OAL138,139 and it has been suggested 
that geographic regional differences may occur or 
that methodological differences in detection of C. 
psittaci may contribute to the discrepant data.140 
Notwithstanding the still controversial nature 
of the association of chlamydial infection with 
lymphoma, the studies by Ferreri et al.132 in the 
Italian population provide compelling evidence 
that chronic C. psittaci infection of monocytes/
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macrophages may play a role in the progression 
of OAL in some populations. The authors pointed 
to the role of H. pylori infection in gastric MALT 
lymphomas as a precedent for chronic bacterial 
infections playing a role in cancer development 
and progression, and the evidence presented for 
a role of C. psittaci infection in OAL certainly 
justifies further investigation.
D. Lymphogranuloma Venereum, 
Chlamydia, and Monocytes
Lymphogranuloma venereum (LGV) is a sexually 
transmitted infection caused by C. trachomatis 
serovars L1, L2, and L3 and primarily infects 
the lymphatics rather than being confined to the 
epithelium. The LGV serovars have a trophism 
for lymphoid cells and evidence suggests that 
macrophages may be the target cells of C. tra-
chomatis infection in LGV.141 In this study, viable 
C. trachomatis LGV serovars were cultured from 
patient lymph nodes. There is recent evidence of 
the re-emergence of LGV, due predominantly to 
the L2 serovar, in men who have sex with men 
(MSM) (reviewed in Ref. 142). It is unknown if 
persistent chlamydial infections play a role in LGV 
disease; however, due to the fact that persistent 
infections and infections in macrophages are more 
resistant to antibiotic therapy, and the documented 
increase in LGV infections, further study of these 
infections may be warranted.
E. Alzheimer’s Disease  
and Multiple Sclerosis
Chlamydia pneumoniae has certainly been dem-
onstrated by PCR in the brain tissue of 20/27 
Alzheimer’s disease (AD) patients but only 3/27 
controls143 and cultures of Chlamydia from two 
AD brain samples identified these as C. pneumo-
niae144 with brain-derived isolates more closely 
related to respiratory isolates than vascular strains 
of C. pneumoniae. Immunohistochemical analysis 
showed that astrocytes, microglia, and neurons 
were all host cells for Chlamydia in AD brain143 
and this is supported by studies with cell lines as 
described earlier. Furthermore, inclusion morphol-
ogy, quantitation of infectious yield, and transcript 
profile were suggestive of an active rather that 
persistent infection, although one study using cell 
lines suggested that microglial cells may be less 
susceptible to infection than astrocytes or neu-
rons.112 In addition, intranasal infection of normal 
BALB/c mice with C. pneumoniae induces the 
deposition of Alzheimer-like amyloid plaques in 
the brains of these animals with the density, size, 
and number of plaques increasing as the infection 
progressed.145 Plaques in mouse brain occurred in 
areas where plaque deposition/pathology occurs 
in human AD brain.145 This study, however, did 
not identify if any particular cell type was pref-
erentially infected. Multiple sclerosis is another 
neurodegenerative disease where C. pneumoniae 
infection is believed by some to play a role. Several 
studies have attempted to identify C. pneumoniae 
and parachlamydial DNA in the CSF of MS pa-
tients.146–153. The results to date have been equivocal 
with some studies reporting a correlation with 
MS as opposed to other neurological diseases or 
with active disease, while other studies showed 
no association. Thus, while the data supporting 
a link between Chlamydia infection and AD is 
stronger than that supporting a relationship with 
MS, it is clear that cell lines characteristic of cell 
types found in the brain can be infected with 
Chlamydia and that there is PCR-based evidence 
of chlamydial DNA in the CSF of patients with 
a number of neurological diseases. It would be 
premature, however, to assert that chlamydial 
infection, either acute or persistent, is a cause of 
any of these conditions.
F. Reactive Arthritis
Although a number of bacterial species have been 
associated with reactive arthritis (RA), epidemio-
logical studies have identified Chlamydia as the 
most common triggering agent of RA in Western 
countries (reviewed in Refs 154 and 155). Approxi-
mately 1–3% of patients with a genital Chlamydia 
infection go on to develop Chlamydia-induced 
arthritis (CIA). C. trachomatis migration from the 
genital epithelium to the affected joint is through 
circulating monocytes/macrophages.155 There is 
increasing evidence of the persistence of bacterial 
products in synovial fluid and viable, metabolically 
active organisms can exist for extended periods in 
the joint, usually in monocytes/macrophages and 
the synovial membrane. Morphological156 and 
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gene expression studies36 suggest that chlamydial 
infections in the joint are persistent. Although not 
completely understood the aetiopathogenesis of 
CIA is believed to be due to a combination of 
(i) a cytokine imbalance following infection in 
a susceptible host (association with HLA-B27), 
(ii) failure to clear the triggering chlamydial 
infection, (iii) persistence of chlamydial antigen, 
(iv) molecular mimicry, where immune responses 
against host HSP60 are triggered by high levels 
of chlamydial HSP60 expression that are char-
acteristic of persistent infections, and (v) altered 
gene expression patterns in host cells within the 
joint including upregulation of growth factors, 
apoptosis-related genes, and adhesion molecules.155 
The presence of persistently infected monocytes/
macrophages in the joint may explain why antibi-
otic therapy has not been successful.157 This may 
also explain why infection persists and escapes 
T cell surveillance since studies have shown that 
Chlamydia-infected macrophages induce death by 
apoptosis in activated T lymphocytes,45,46 provid-
ing a potential mechanism for evasion of the host 
immune response.
VI. CONCLUSIONS AND FUTURE 
DIRECTIONS
Compared to growth in epithelial cell lines such 
as Hep-2 cells, McCoy cells, and HeLa cells, the 
growth of all Chlamydia species in various immune 
cells almost never exceeds the number of infection 
forming units (IFUs) that are used to initiate the 
infection. If isolation of infectious EBs (that are 
able to infect traditional epithelial cell targets) is 
used as the criteria for “infection,” then in many 
cases no infectious Chlamydia are recovered. In 
many immune cell types, however, evidence of 
some chlamydial replication, as evidenced by the 
presence of inclusions, intracellular accumulation 
of chlamydial antigens such as LPS and transcrip-
tion of replication-associated chlamydial genes can 
be demonstrated and this has led to the conclusion 
that in most immune cells infections are persis-
tent and that the developmental cycle does not 
proceed to completion such that fully infectious 
EBs are not produced (summarized in Table II). 
The outcome of infection can be influenced by 
several factors including the infectious dose used 
and also the stage of development of a particular 
cell lineage. Early studies with peritoneal mac-
rophages and PMNs demonstrated that at high 
MOIs, many chlamydial species were cytotoxic 
for both these cell types, while at lower MOIs 
cells could become persistently infected and in 
some cases fully infectious EBs were recovered. 
In most of the studies in the literature, only a 
single or at most two infectious doses are used 
and this is perhaps a shortcoming that may have 
given an incomplete picture of the ability of a 
particular cell to support infection. In addition, 
the fact that there are almost no data available on 
the infectious dose required to initiate a genital 
or respiratory infection in a human host makes 
it difficult to predict from in vitro studies if a 
chlamydial infection will follow an acute course 
or become persistent. Furthermore, it is not pres-
ently possible to quantitate Chlamydia numbers 
in affected tissues such as blood vessels, fallopian 
tubes, or conjunctival tissues so that correlations 
can be made with in vitro studies.
Many immune cells develop along defined 
developmental pathways from hemopoietic stem 
cells to fully differentiated end-stage cells. It cannot 
be assumed that cells of a particular lineage will 
show the same susceptibility to infection at all 
developmental stages. This is well demonstrated in 
studies with cells and cell lines of the monocyte/
macrophage lineage where blood monocytes or 
early monocyte-like cell lines are less susceptible 
to infection than more mature macrophages. In-
deed, in many studies maturation of monocytes by 
plastic adherence for three to eight days increased 
the susceptibility of these cells to infection with 
various chlamydial species. Further studies com-
paring susceptibility of classically activated versus 
alternatively activated macrophages and myeloid 
dendritic cells versus plasmacytoid dendritic cells, 
for example, will be required to fully define the 
infection potential of these cell lineages. 
Another issue that should be considered is 
how representative the infection techniques em-
ployed in in vitro studies are of infection in vivo. 
In most in vitro studies, lysates or supernatants 
of infected immune cells are cultured on epithe-
lial cell monolayers to determine the presence of 
infectious Chlamydia. Although this approach has 
demonstrated the lack of infectious Chlamydia in 
many immune cell types, co-culture systems of 
infected immune cells with other cell types have 
demonstrated that infection is transferred to the 
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target cell. For example, infected dendritic cells are 
able to infect monocytes, and THP-1 and U-937 
monocytic cell lines become infected by co-culture 
with infected HeLa cells and go on to produce in-
fectious EBs, whereas infection of these monocytic 
cell lines with purified Chlamydia did not result in 
a productive infection. Most in vitro studies also 
employ epithelial cells grown as monolayers on 
tissue culture flasks or plates. The same cells grown 
as polarized epithelial layers on transwell systems 
are more representative of epithelial barriers and 
it has been demonstrated in many studies that 
receptor expression158 and cytokine secretion,159 
to name but two functions, differ greatly at the 
apical and basolateral surfaces of cells grown as 
polarized monolayers, differences that would not 
be seen in normal monolayer cultures. It is not 
unreasonable, therefore, to expect that binding 
and internalization of Chlamydia may also differ 
in cells grown as polarized monolayers. 
The increasing number of in vivo studies 
demonstrating infected immune cells, monocytes 
in particular, in peripheral blood of both normal 
blood donors and patients with conditions such 
as CAD, together with the in vitro infection 
study data, suggest that immune cells are not a 
significant host cell type for chlamydial replica-
tion but serve more as a “Trojan horse” for dis-
semination of Chlamydia from the site of initial 
infection (genital and respiratory epithelium) to 
distant tissue sites such as blood vessels, joints, 
and lymph nodes. 
As well as using these cells as a free ride to 
other tissues, Chlamydia species can modulate the 
function of infected cells in order to avoid the 
host immune response and to facilitate entry into 
tissues such as the CNS. Chlamydial infection of 
both PMNs and monocytes delays or prevents 
apoptosis in these cells. In the case of infected 
PMNs, apoptosis is delayed long enough (96 h) 
such that C. pneumoniae is able to complete at 
least one developmental cycle. Infected PMNs 
can then be phagocytosed by alveolar macrophages 
and transported from the lung to other tissues or, 
alternatively, EBs released by PMNs can infect 
epithelial cells in the lung. Infection of monocytes 
results in the modulation of receptors for TNFα, 
IL-1β, and IFNγ potentially protecting infected 
monocytes from the host innate immune response. 
Infected monocytes also induce apoptotic cell 
death in activated T lymphocytes, a function that 
is mediated in part by the production of TNFα. 
This may allow chlamydial infections to persist 
by avoiding T cell surveillance. Thus, Chlamydia-
infected monocytes produce an inflammatory 
cytokine to evade the T cell response while at 
the same time avoiding any deleterious affects 
of TNFα by downregulating TNFR expression. 
Chlamydial infection of monocytes also affects 
lipid metabolism and adhesion molecule expression 
by these cells. This results in foam cell formation, 
increased adherence to vascular endothelium, and 
potentially increased numbers of cells able to cross 
the blood-brain barrier, which may play a role in 
CAD and neurodegenerative diseases.
Chlamydial infection of dendritic cells can 
also alter DC function, particularly cytokine 
secretion patterns and expression of surface 
markers such as MHC class II, CD40, CD80, 
and CD86, all of which are involved in activa-
tion of naive T cells. Chlamydia-infected BALB/c 
dendritic cells induce strong Th2 responses 
to a model allergen, OVA, in transgenic D10 
cells whereas noninfected DCs induce a Th1 
phenotype in these cells, and infected DC also 
exacerbated allergic airways disease in an animal 
model. This suggests that in atopic individuals, 
Chlamydia infection could elicit a nonprotective 
Th2 response that permits chlamydial persistence 
while at the same time exacerbating allergic 
responses to nonrelated environmental antigens. 
Although our studies used Th2-prone BALB/c 
mice, other investigators have recently shown 
that low dose respiratory C. pneumoniae infection 
and concomitant allergen exposure of C57BL/6 
mice enhanced allergic sensitization, and these 
effects could be recapitulated by adoptive trans-
fer of allergen-pulsed DCs from infected mice. 
Although this study did not determine if DCs 
were actually infected with C. pneumoniae, the 
data show that chlamydial respiratory infection, 
even in Th1-prone C57BL/6 mice, can affect 
DC function in a way that enhances allergic 
responses. Collectively, these studies may explain 
the epidemiological linkage between C. pneumo-
niae infection and asthma; however, future studies 
of C. pneumoniae infection of human dendritic 
cells from atopic and normal individuals will be 
required to confirm this association. The age of 
DC exposure to chlamydial infection is another 
factor that can influence the outcome of allergic 
airways disease in a mouse model, with exposure 
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to Chlamydia during the neonatal period having 
the greatest affect on subsequent airways disease. 
Thus, exposure of DCs to Chlamydia (and other 
pathogens) during the neonatal period may have a 
profound influence on immunity in adult life.
The mechanisms that allow Chlamydia to 
modulate host cell function are only beginning 
to be understood. Chlamydia do possess a type III 
secretion system that allows entry of chlamydial 
proteins into the host cell cytoplasm and this may 
provide a means of targeting host cell signaling 
and metabolic pathways. For example, C. pneu-
moniae secretes a protein (CP0236) that impairs 
IL-17–mediated signaling160 by inhibiting NF-
κΒ signaling via interaction of CP0236 with 
host cell Act1. C. trachomatis secretes a number 
of proteins including some that interact with 
NF-kB signaling pathways. Examples include 
the protease Tsp, which degrades p65,161 and the 
deubiquitinase ChlaDub1, which deubiquitinates 
IkBa, preventing its degradation to release NF-
κΒ.162 It is tempting to speculate that Chlamydia 
may have evolved multiple mechanisms to target 
this important immune activation pathway as a 
means of surviving within immune cells in order 
to gain access to other target tissues and as a 
means of controlling the host immune response 
to ensure persistence.
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